Advances in treatment 

Treatment

Managed - Branded - Compliant

- Custom Scale to Grow
- Digital & Phone Branded with recording & Opt in information
- Digital Campaign includes Terms, Conditions, Privacy Policy, Opt-out & Agreement info
- NO Brokers or Re-Sellers

Benefits of CGM Campaign include Branding, Exclusive, Compliant and 1 Year Prescriptions


For more information, visit:
https://sites.google.com/view/cgm-managed-campaign/home

Novo Nordisk’s oral GLP-1 agonist Rybelsus – a key part of plans to inject growth into its diabetes franchise – has been approved for marketing in Japan.

The green light from the Japanese Ministry of Health, Labour and Welfare (MHLW) follows an FDA approval for Rybelsus (semaglutide) last October, and a recommendation for approval in the EU in February.

Rybelsus is the first and so far only oral alternative to injectable GLP-1 agonists such as Eli Lilly’s Trulicity (dulaglutide) and Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide), and has been tipped as a future blockbuster brand.

Novo Nordisk has a lot riding on the new drug, as the company’s diabetes franchise has been hit by competition from Trulicity as well as downwards pressure on pricing in the US from payers.

Read more: http://www.pmlive.com/pharma_news/novo_nordisk_gets_another_ok_for_oral_glp-1_drug_rybelsus_1343323

Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus - PMLiVE

Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus - PMLiVE

Do potatoes really increase the chances of one getting diabetes by causing insulin resistance?

JDRF the leading global organization funding type 1 diabetes (T1D) research, funded $121.5 million directly and helped generate more than $400 million in total T1D research funds from nonprofits, government, and industry to propel a year of remarkable breakthroughs in 2019, JDRF announced today. JDRF research funding increased by 10 percent over the previous year.

Read more: https://prn.to/320OWbH

Stroke is the second largest cause of death among people above the age of 60. The diagnostic and treatment of patients is responsible for a huge investment in the healthcare market. The rise in incidence and prevalence of chronic diseases has boosted the stoke management market. Furthermore, the global geriatric population has increased, which amplified the demand for technologically advanced healthcare facilities. Inclination of today’s generation towards tobacco and increase in diabetes patients drive the stroke management market. 

A treatment in the first few minutes of a stroke can lower the risk of death. The standard procedures to detect strokes provide only 40 to 80 percent of accuracy. However, a new device worn like a visor can detect strokes within seconds with an accuracy of more than 90 percent. In addition, the device can help transfer the patients with large vessel occlusion directly to hospitals with endovascular capabilities, routing around the less-equipped facilities and saving valuable time. The device operates on low-level radio waves through brain and records the waves passing through the fluids of brain. When someone is experiencing a stroke, the brain’s fluids undergo some changes, which produce irregularities in the brain pattern. The device records such asymmetries to detect the symptoms of strokes and take necessary actions accordingly. 

It is essential to speed up the post-stroke recovery process. A device is developed that can send data directly to doctors and help closely monitor stroke patients. Lizzy McAninch, a patient with an experience of stroke explained in an interview with BBC news, “The device is equipped with sensors that evaluates properly working muscles of post-stroke patients. Furthermore, it pinpoints the areas affected by the attack, and targets therapies to improve health.” 

The device looks like small sticking plasters, which are easy to wear and can be used for a long time. The sensors send data even after patients are finished with their therapies and exercises. The data provide doctors a reliable source of information and helps them decide course of action for improvement of a patient. The manufacturers believe that the main challenge was to bind multiple sensors together on a small platform, so that patients feel comfortable to wear it during their exercises. Along with numerous advanced sensors, the prototype embeds a computing unit, power supplies, and Wi-Fi, which can give a real-time feedback to doctors about a patient’s health. 

Numerous startups have developed tools to speed up the thrombectomy procedures. A Rochester-based startup has invented a new device to improve the treatment of ischemic strokes. The device provides surgeons a free movement around the desired areas and allows an effective delivery in thrombectomy surgeries. For now, developers are testing the prototype and hoping for its market availability by the end of summer. In addition, healthcare companies are now interested to use artificial intelligence (AI) to scan hundreds of National Health Service (NHS) stroke patients in a year. The increased number of stroke patients has forced doctors to analyze their scans faster and more accurately than ever. As a result, in several cases, experts came up with different conclusions after reading a same scan multiple times. This confusion can be solved with the help of AI. 

Chris Mansi, the Founder and CEO of Viz.ai has been developing algorithms to save brain cells of stroke patients. The product is designed to analyze CT scans of stroke patients automatically. It uses an algorithm to spot blockages in brain blood vessels. Whenever, AI thinks it has found a blockage, it sends an alert to specialists and ask for their opinion. Furthermore, the software remembers specific images it finds important. Mansi explained, “The AI is not cutting anyone’s job out, however, this helps create a parallel workflow that can detect brain attack. As a lot of patients are not getting a faster treatment, AI-based technology has opened new gates in healthcare sector.” 

The use of advanced technologies to detect stroke and the involvement of AI have boosted the stroke management market. In its recent report on the global stroke management market, Allied Market Research outlines competitive situations and trends, provides insights sales, revenue, market share of key segments, and explores leading manufacturers. Furthermore, the report is helpful for market players, investors, and entry-level companies to understand the market conditions and take necessary steps to devise strategies for the future. 

Source: https://www.alliedmarketresearch.com/stroke-diagnostics-and-therapeutics-market 

Contact: help@alliedmarketresearch.com 

Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients with type I diabetes.

The data, presented for the first time at ENDO 2018, the Endocrine Society’s 100th Annual Meeting & Expo, in Chicago, showed that the drug is linked with statistically significant improvements in HbA1c in patients with the condition, with a mean difference of from baseline to month six of –4.4 mmol/mol.

The study also showed no change in the number of patients reporting either diabetic ketoacidosis (DKA) or severe hypoglycaemia after starting treatment with Toujeo (Gla-300).

Read more: http://www.pharmatimes.com/news/real_world_data_back_sanofis_toujeo_for_type_i_diabetes_1228401